Conference Coverage
Conference Coverage
VIDEO: Interchangeability of biosimilars and parent compounds raise potential efficacy issues
WAILEA, Hawaii Biosimilars are coming to dermatology, but their impact from a clinical and insurance standpoint has yet to be determined,...
Conference Coverage
Fixed combination topical shows promise for psoriasis
MIAMI – The first study to evaluate a fixed-dose combination of a potent topical steroid combined with tazarotene evaluates multiple safety and...
Conference Coverage
Initial suboptimal responders to secukinumab usually bloom later
VIENNA – Consider sticking with secukinumab longer in the 1 in 20 patients who don’t achieve a PASI 75 response in the first 12 weeks; most will...
Conference Coverage
Secukinumab tames severe scalp psoriasis
VIENNA – The majority of patients with moderate to severe scalp psoriasis achieved at least 90% improvement after 12 weeks on secukinumab.
Conference Coverage
Ixekizumab proves highly effective for palmoplantar, scalp psoriasis
VIENNA – Unprecedented response rates were seen in palmoplantar disease.
Conference Coverage
Latest ixekizumab safety data called ‘very reassuring’
VIENNA – There are no signs to date of any cumulative toxicities.
Conference Coverage
VIDEO: Tune in to psoriasis patients’ quality of life
LAS VEGAS – Physicians often fail to predict the impact of disease on quality of life in their psoriasis patients, which can help guide treatment...
Conference Coverage
Pediatric psoriasis linked to multiple psychiatric comorbidities
VIENNA – The high level of emotional distress that can be caused by psoriasis is reflected in significantly increased risks for depression, eating...
Conference Coverage
Infliximab biosimilar posts mostly reassuring data in Norway’s NOR-SWITCH study
WASHINGTON – Data from the first randomized trial of switching from an originator biologic to a biosimilar of the originator indicate that the...
Conference Coverage
VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy
LAS VEGAS – Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said...